Literature DB >> 16382054

Alterations in DNA repair gene expression under hypoxia: elucidating the mechanisms of hypoxia-induced genetic instability.

Ranjit S Bindra1, Paul J Schaffer, Alice Meng, Jennifer Woo, Kårstein Måseide, Matt E Roth, Paul Lizardi, David W Hedley, Robert G Bristow, Peter M Glazer.   

Abstract

Hypoxia is a common feature of solid tumors and is associated with genetic instability and tumor progression. It has been shown previously that alterations in the expression of DNA repair genes in response to hypoxic stress may account for a proportion of such genetic instability. Here, we demonstrate that the expression of RAD51, a critical mediator of homologous recombination (HR), is repressed by hypoxia in numerous cell lines derived from a wide range of tissues. Repression of this gene by hypoxia occurs in a cell cycle- and hypoxia-inducible factor (HIF)-independent manner, and decreased RAD51 expression was observed to persist during the post-hypoxic period. In addition, decreases in Rad51 expression were correlated with functional impairments in HR repair in hypoxic and post-hypoxic cells. Based on these data, we propose a novel mechanism of hypoxia-induced genetic instability via suppression of the HR pathway in cancer cells within the tumor microenvironment.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382054     DOI: 10.1196/annals.1339.049

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  27 in total

Review 1.  APE1/Ref-1 role in redox signaling: translational applications of targeting the redox function of the DNA repair/redox protein APE1/Ref-1.

Authors:  Mark R Kelley; Millie M Georgiadis; Melissa L Fishel
Journal:  Curr Mol Pharmacol       Date:  2012-01       Impact factor: 3.339

Review 2.  Targeting DNA repair in cancer: current state and novel approaches.

Authors:  Apostolos Klinakis; Dimitris Karagiannis; Theodoros Rampias
Journal:  Cell Mol Life Sci       Date:  2019-10-14       Impact factor: 9.261

3.  EGFR Mutations Compromise Hypoxia-Associated Radiation Resistance through Impaired Replication Fork-Associated DNA Damage Repair.

Authors:  Mohammad Saki; Haruhiko Makino; Prashanthi Javvadi; Nozomi Tomimatsu; Liang-Hao Ding; Jennifer E Clark; Elaine Gavin; Kenichi Takeda; Joel Andrews; Debabrata Saha; Michael D Story; Sandeep Burma; Chaitanya S Nirodi
Journal:  Mol Cancer Res       Date:  2017-08-11       Impact factor: 5.852

4.  CTGF is a therapeutic target for metastatic melanoma.

Authors:  E C Finger; C-F Cheng; T R Williams; E B Rankin; B Bedogni; L Tachiki; S Spong; A J Giaccia; M B Powell
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

Review 5.  HypoxamiRs and cancer: from biology to targeted therapy.

Authors:  Harriet E Gee; Cristina Ivan; George A Calin; Mircea Ivan
Journal:  Antioxid Redox Signal       Date:  2013-11-22       Impact factor: 8.401

6.  SIGN: similarity identification in gene expression.

Authors:  Seyed Ali Madani Tonekaboni; Venkata Satya Kumar Manem; Nehme El-Hachem; Benjamin Haibe-Kains
Journal:  Bioinformatics       Date:  2019-11-01       Impact factor: 6.937

Review 7.  Hypoxia, inflammation, and the tumor microenvironment in metastatic disease.

Authors:  Elizabeth C Finger; Amato J Giaccia
Journal:  Cancer Metastasis Rev       Date:  2010-06       Impact factor: 9.264

Review 8.  Redox regulation of DNA repair: implications for human health and cancer therapeutic development.

Authors:  Meihua Luo; Hongzhen He; Mark R Kelley; Millie M Georgiadis
Journal:  Antioxid Redox Signal       Date:  2010-06-01       Impact factor: 8.401

9.  Hypoxia modulates A431 cellular pathways association to tumor radioresistance and enhanced migration revealed by comprehensive proteomic and functional studies.

Authors:  Yan Ren; Piliang Hao; Bamaprasad Dutta; Esther Sok Hwee Cheow; Kae Hwan Sim; Chee Sian Gan; Sai Kiang Lim; Siu Kwan Sze
Journal:  Mol Cell Proteomics       Date:  2012-11-30       Impact factor: 5.911

Review 10.  Inhibiting the DNA damage response as a therapeutic manoeuvre in cancer.

Authors:  N J Curtin
Journal:  Br J Pharmacol       Date:  2013-08       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.